Versant Venture Management, LLC

SAN FRANCISCO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$109.1M2026 Q3
Positions8
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%

Versant Venture Management, LLC reported 8 positions worth $109.1M as of September 30, 2026 (13F filed November 13, 2026). Largest holding: GLUE (34.8%). Biggest move: add CTNM ($10.1M).

8 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 GLUEMonte Rosa Therapeutics$37.9M34.78%3,180,780——-23.2%
▸ 2 IPSCCentury Therapeutics$20.8M19.07%12,166,109——-4.1%
▸ 3 CTNMContineum Therapeutics$17.3M15.90%1,292,628——-26.5%
▸ 4 JBIOJade Biosciences$13.9M12.77%991,783———
▸ 5 LENZLENZ Therapeutics$10.2M9.35%2,656,888——+7.6%
▸ 6 CRSPCRISPR Therapeutics$8.2M7.55%148,831——-27.0%
▸ 7 SKYESkye Bioscience$404.0K0.37%250,962——-32.3%
▸ 8Tempest Thera…Tempest Therapeutics$225.1K0.21%269,772———

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Versant Venture Management, LLC hold as of Q3 2026?

Versant Venture Management, LLC reported 8 positions worth $109.1M in its Q3 2026 13F filing. Largest positions: GLUE (34.8%), IPSC (19.1%), CTNM (15.9%), JBIO (12.8%) and LENZ (9.4%).

What did Versant Venture Management, LLC buy in Q3 2026?

New positions: SKYE. Added to: CTNM.

What did Versant Venture Management, LLC sell in Q3 2026?

Sold out entirely: Skye Bioscience, Inc..

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.